Does Saxenda affect your kidneys?

GLP-1 receptor agonists (applies to Saxenda) renal dysfunction. Moderate Potential Hazard, Moderate plausibility. There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors.

drugs.com - Saxenda Disease Interactions - Drugs.com

What is an average size waist for a woman?

38.7 inches The bottom line The average American woman's waist size is 38.7 inches. Also, the average American woman is 63.6 inches tall and weigh...

Last updated May 25, 2018

What kind of milk is best for weight loss?

Almond milk - 26 calories It's clear almond milk is the winner when it comes to the least calories and those looking for weight loss. This is...

Last updated Apr 18, 2022

Promotion

Saxenda Disease Interactions

There are 5 disease interactions with Saxenda (liraglutide).

Major GLP-1 receptor agonists (applies to Saxenda) pancreatitis Major Potential Hazard, Moderate plausibility. The use of GLP-1 receptor agonists has been associated with rare reports of acute pancreatitis. Other antidiabetic therapies should be considered in patients with a previous history of pancreatitis, although it is not known if they are at increased risk. Patients receiving treatment with GLP-1 receptor agonists should be observed carefully for signs and symptoms of pancreatitis. If this diagnosis is suspected, the treatment should be discontinued immediately and appropriate management should be initiated. Treatment with GLP-1 receptor agonists should be permanently discontinued if pancreatitis is confirmed. References "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc (2005): "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline (2014): "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company (2014): "Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2015): View all 4 references Major GLP-1 receptor agonists (applies to Saxenda) thyroid carcinoma Major Potential Hazard, Moderate plausibility. Applicable conditions: Multiple Endocrine Neoplasia Type II GLP-1 receptor agonist antidiabetic drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Carcinogenicity studies in rodents and limited postmarketing data suggest that GLP-1 inhibitors may cause a dose-related and treatment duration-related increase in risk of thyroid C-cell tumors, although a causal relationship has not been established. References "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc (2005): "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2010): "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline (2014): "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company (2014): "Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2015): View all 5 references Major Liraglutide (applies to Saxenda) depression Major Potential Hazard, Moderate plausibility. Therapy with liraglutide should be administered cautiously in patients with depression or any mood or behavior disorder because of the potential for suicidal thoughts or behavior. The drug should be avoided in patients with a history of suicidal attempts or active suicidal ideation. References "Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2015): Moderate GLP-1 receptor agonists (applies to Saxenda) renal dysfunction Moderate Potential Hazard, Moderate plausibility. There have been reports of acute renal failure and worsening of chronic renal failure sometimes requiring hemodialysis in patients treated with GLP-1 receptor inhibitors. Some of these events occurred in patients without known underlying renal disease. These drugs should be used with caution in patients with renal impairment, especially during treatment initiation or dose escalation. Patients should be monitored, especially if they report severe gastrointestinal reactions such as nausea, vomiting, diarrhea, or dehydration. The frequency of gastrointestinal events is increased as renal function declines. There is limited clinical experience with most of these drugs in patients with severe renal impairment. References "Product Information. Symlin (pramlintide)." Amphastar Pharmaceuticals Inc (2005): "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc (2005): "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2010): "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company (2014): View all 4 references Moderate Liraglutide (applies to Saxenda) cardiovascular disease Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Cerebrovascular Disease Liraglutide can increase the resting heart rate and it should be used with caution in patients with history of cardiovascular disease and cerebrovascular disease. Heart rate should be monitored regularly, and patients should inform their healthcare providers of any symptoms such as palpitations and racing heartbeat appear while at rest. References "Product Information. Saxenda (liraglutide)." Novo Nordisk Pharmaceuticals Inc (2015):

How long does it take for fat to leave the body?

The American Council on Exercise says a 1 percent body fat loss per month is safe and achievable. Given that math, it could take a woman with...

Last updated Mar 26, 2022

What is the skinny shot for weight loss?

Skinny Shots are a mixture of B vitamins, amino acids, and lipotropic agents. The Skinny Shot is a special formula of liver supporting nutrients...

Last updated Apr 5, 2020

Learn More »

Promotion

Saxenda drug interactions

There are 250 drug interactions with Saxenda (liraglutide).

Saxenda alcohol/food interactions

There are 2 alcohol/food interactions with Saxenda (liraglutide).

Drug Interaction Classification These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

drugs.com - Saxenda Disease Interactions - Drugs.com

Why do I bloat after every meal?

Eating a lot of salty food and carbohydrates can make you feel bloated, as can swallowing air when you eat too fast or drink a lot of fizzy drinks....

Last updated Jun 28, 2020